Navigation Links
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
Date:6/9/2009

selective MAO inhibitors, such as phenelzine sulfate, interfere with the breakdown and elimination of tyramine in the body. Selective MAO-B inhibitors do not interfere with tyramine breakdown and elimination. Patients who take nonselective MAO inhibitors need to be cautious with the foods they eat to prevent an abnormal build-up of tyramine, which could lead to an episode of extremely high blood pressure, potentially leading to stroke or heart attack.

This study was performed as part of a Phase IV commitment to the U.S. Food and Drug Administration (FDA) at the time of AZILECT approval. The results of this study have been submitted to FDA, and Teva Neuroscience intends to work with FDA to appropriately incorporate these results into the label for AZILECT.

About the Study

The tyramine trial was a double-blind, placebo-controlled, randomized, dose-ranging study of rasagiline using a positive control (phenelzine) and a comparator drug (selegiline). In the study, 179 healthy male and female volunteers, aged 40 to 70 years, entered a run-in tyramine challenge test with escalating doses of oral tyramine from 25 mg up to 800 mg administered under fasting conditions. TSF was calculated as the tyramine dose associated with 3 consecutive increases from baseline in SBP >/=30 mm Hg over >/=10 minutes (tyramine pressor dose) in period 1 divided by the dose associated with the same change in SBP in period 3. Nonselective comparator, phenelzine, caused the highest geometric mean TSF of 17.32 +/- 12.76. Geometric mean TSF for rasagiline 1 mg once daily, the maximum approved dose, was 2.03 compared with 1.50 for pooled placebo and 2.47 for selegiline.

About AZILECT(R)

AZILECT(R) (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.

<
'/>"/>

SOURCE Teva Neuroscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
2. LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
3. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
4. Document Management Inefficiencies Cost Clinical Study Sites Time, Money
5. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
6. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
7. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
8. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
9. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... LONDON and BOSTON , June ... market is set to reach $127 billion by 2018, accounting ... to the recently released Orphan Drug Report 2013 ... its clients, needs in regard to this growing segment of ... core product database to include in-depth, fact-based orphan drug analysis ...
(Date:6/17/2013)... June 17, 2013 With the huge success ... of the Chief Medical Officer Summit for Emerging Life Science ... take place in San Francisco on November 4-5, 2013 at ... first time, West Coast Chief Medical Officers at biotechs have ... Stoner, Managing Director of MPM Capital. Valerie Bowling, Executive Director ...
(Date:6/17/2013)... MUNDELEIN, Ill. , June 17, 2013 /PRNewswire/ ... – News), a biotechnology company providing value-added ingredients ... it will be presenting a new meat application ... (IFT) show in Chicago , ... Trim ingredients can replace more expensive/chemically-modified ingredients in ...
(Date:6/17/2013)... DUBLIN , June 17, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/9rwvs2/north_america ) has announced the addition of ... Market - by Formulations [Liposomes, Microspheres, & ... Prefilled, Pen, Needle Free & Auto Injectors] ... to their offering. ,      ...
Breaking Biology Technology:Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3
... N.J., Dec. 17 National Stem,Cell Holding, Inc. ... financial information, quotations and press releases are,posted on ... OTCIQ is a secure, web-based portal that ... facilitate communication with the,marketplace, promote transparency, mitigate risk, ...
... Genzyme Corp.,(Nasdaq: GENZ ) announced today that ... a supplemental indication for Thyrogen(R) (thyrotropin,alfa for injection) ... ablate,or destroy, the remaining thyroid tissue in patients ... is a procedure that patients,commonly undergo when being ...
... DIEGO, Dec. 17 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ... appointed to,the company,s Board of Directors. Mr. Turner brings ... and will also serve on,the company,s audit committee., ... said Dr. Christopher S.,Henney, Chairman of the Board of ...
Cached Biology Technology:National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 3Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 4SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3
(Date:6/14/2013)... Cliffs of Dover" was a morale-boosting song that lifted ... mark the point at which England is closest to ... structures made of the chalky, white shells that envelop ... . "Ehux" is a coccolithophore, with an exoskeleton made ... the alga,s "armor" forms releases carbon dioxide, Ehux can ...
(Date:6/14/2013)... 12 June 2013: Data presented at EULAR 2013, the ... that novel antibody biomarkers could significantly improve diagnosis in ... UH-RA.1, UH-RA.9, UH-RA.14 and UH-RA.21 were investigated; as ... were present in both early and seronegative disease, ... and ACCP -negative patients testing positive. , RA ...
(Date:6/13/2013)... that combining improved oyster restoration methods with limits on ... population back to the Bay in a much shorter ... of the University of Maryland Center for Environmental Science,s ... restoration options to see which ones would have the ... we developed suggests that oysters should be able to ...
Breaking Biology News(10 mins):Chalking up a marine blooming alga: Genome fills a gap in the tree of life 2Chalking up a marine blooming alga: Genome fills a gap in the tree of life 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 4Oysters could rebound more quickly with limited fishing and improved habitat 2
... remains the subject of "best guesses," and as a ... perceptions and politics, rather than an objective assessment of ... , Simon Hay and Robert Snow (Kenya Medical Research ... been almost 40 years since the last global map ...
... be arranged along a ladder of intelligence—a sort of ... by our close relatives, the primates, all the way ... past decade, this ladder has been challenged by claims ... animals. For example, spotted hyenas establish hierarchies in which ...
... fight viruses is also involved in keeping cancer cells alive, ... The anti-viral molecule, called TBK-1, was found to be essential ... to a treatment for fighting cancer, the researchers report in ... surprise that this mechanism is involved in cancer cell survival, ...
Cached Biology News:Fishy cooperation 2Natural anti-viral enzyme helps keep cancer cells alive, researchers find 2
... IgY Antibodies Hypothetical protein FLJ20644, likely ... Protein Accession #: NP_060387.1 ... Genbank Definition: chromosome 14 open ... phosphatase subunit gene g4-1 [Homo sapiens] ...
Request Info...
Lineage cocktail 1 (lin 1) 50 tests...
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Biology Products: